ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase IV development as a treatment for Parkinson's disease psychosis. It is also developing AGN XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. The product candidates in the company's pipeline emanate from discoveries made using its proprietary drug discovery platform.
This one has been getting a lot of talk for their upcoming NUPLAZID drug which got board approval and is expected to have a favorable FDA approval on May 1. It's had one heck of a round-bottom over the last few weeks/months. Checking out the year chart it looks like it is right on the precipice of a key level. If it can hold this ~$33 level and does in fact get that approval it could have some room to run. If not.... well that's a lot of overhead to compete with...
Following this one pretty closely. It's overbought and sitting right up against the 200MA after close today. I'm thinking it heads back down tomorrow and floats between the $30-$33 range for awhile.
Agree that it has a few more down days in it, but I think that May 1 decision will be what decides it. Might be a 'buy the hype, sell the news' kind of pattern where it gets a nice run for a week or so before then drops in the days leading up to the announcement before either going higher if it is good or dropping sharply if not.
ACAD continued upwards today and stayed above the 200MA. Shooting star formed today that could be a bearish reversal pattern.
Why Shares of ACADIA Pharmaceuticals Inc. Jumped Today Rumors of an acquisition are swirling, pushing the biopharma's share price higher. What: Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharma focused on diseases of the central nervous system, were up more than 12% as of 3:30 p.m. ET on rumors that AstraZeneca PLC (ADR) (NYSE:AZN) is eyeing the company as a potential acquisition candidate. Read full article here: http://www.fool.com/investing/gener...-of-acadia-pharmaceuticals-inc-jumped-to.aspx
Reported after close today (11/7/16) Earnings: EPS -$0.61 Revenue $5.3M Estimates: EPS -$0.56 Revenue $2.9M Up 11.05% after hours
Edited Transcript of ACAD earnings conference call or presentation 7-Nov-16 10:00pm GMT Q3 2016 ACADIA Pharmaceuticals Inc Earnings Call SAN DIEGO Nov 8, 2016 (Thomson StreetEvents) -- Edited Transcript of ACADIA Pharmaceuticals Inc earnings conference call or presentation Monday, November 7, 2016 at 10:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Lisa Barthelemy ACADIA Pharmaceuticals Inc. - Senior Director of IR * Steve Davis ACADIA Pharmaceuticals Inc. - President, CEO * Todd Young ACADIA Pharmaceuticals Inc. - EVP, CFO * Terry Moore ACADIA Pharmaceuticals Inc. - EVP, Chief Commercial Officer * Serge Stankovic ACADIA Pharmaceuticals Inc. - EVP, Head of Research & Development ================================================================================ Conference Call Participants ================================================================================ * Cory Kasimov JPMorgan - Analyst * Alan Carr Needham & Company - Analyst * Ritu Baral Cowen and Company - Analyst * Charles Duncan Piper Jaffray & Co. - Analyst * Tazeen Ahmad BofA Merrill Lynch - Analyst * Jason Butler JMP Securities - Analyst * Paul Matteis Leerink Partners - Analyst * Bert Hazlett BTIG, LLC - Analyst ================================================================================ Presentation -------------------------------------------------------------------------------- Operator [1] -------------------------------------------------------------------------------- Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals' third-quarter 2016 financial results conference call. My name is Suzanne and I will be your coordinator for today. (Operator Instructions). I would now like to turn the presentation over to Lisa Barthelemy, Senior Director of Investor Relations at ACADIA. Please proceed. -------------------------------------------------------------------------------- Lisa Barthelemy, ACADIA Pharmaceuticals Inc. - Senior Director of IR [2] -------------------------------------------------------------------------------- Thank you, Suzanne. Good afternoon and welcome to ACADIA's third-quarter 2016 financial results conference call. This call is being recorded, and an archived copy will be available on our website at www.ACADIA-pharm.com through November 21, 2016. Joining me on the call today from ACADIA are Steve Davis, our President and Chief Executive Officer; Dr. Serge Stankovic, our Executive Vice President and Head of Research and Development; Terry Moore, our Executive Vice President and Chief Commercial Officer; and Todd Young, our Executive Vice President and Chief Financial Officer. Before we proceed, I would first like to remind you that during our call today we will be making a number of forward-looking statements, including statements regarding our strategy, including the timing, results, or implications of clinical trials; other development efforts for regulatory approval; the benefits or advantages to be derived from future approvals of, and the commercial potential for our product candidates, in each case including NUPLAZID or pimavanserin; future commercial and financial results; and the future development and commercialization of our product candidates. During our call today we may use words such as anticipate, believe, could, expect, intend, may, plan, potential, predict, project, should, or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. These forward-looking statements are based on current information, assumptions, and expectations that are inherently subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors and other risks associated with our business can be found in our filings made with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of today's date. ACADIA disclaims any obligation to update these forward-looking statements. I will now turn the call over to Steve Davis, our President and Chief Executive Officer.
